KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2026)

Amneal Pharmaceuticals has reported Revenue over the past 9 years, most recently at $814.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 11.47% year-over-year to $814.3 million; the TTM value through Dec 2025 reached $3.0 billion, up 8.05%, while the annual FY2025 figure was $3.0 billion, 8.05% up from the prior year.
  • Revenue for Q4 2025 was $814.3 million at Amneal Pharmaceuticals, up from $784.5 million in the prior quarter.
  • Over five years, Revenue peaked at $814.3 million in Q4 2025 and troughed at $493.1 million in Q1 2021.
  • A 5-year average of $625.6 million and a median of $613.4 million in 2022 define the central range for Revenue.
  • On a YoY basis, Revenue climbed as much as 145.84% in 2021 and fell as far as 1.09% in 2021.
  • Year by year, Revenue stood at $536.9 million in 2021, then grew by 13.57% to $609.8 million in 2022, then grew by 1.18% to $617.0 million in 2023, then grew by 18.4% to $730.5 million in 2024, then increased by 11.47% to $814.3 million in 2025.
  • Business Quant data shows Revenue for AMRX at $814.3 million in Q4 2025, $784.5 million in Q3 2025, and $724.5 million in Q2 2025.